PERKINELMER INC 

$115.24
119
-$1.06-0.91% Monday 20:03

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
41.45
股息殖利率
0.24%
股息
0.28

即將到來

股息

0.24%股息殖利率
Feb 26
$0.07
Nov 25
$0.07
Aug 25
$0.07
May 25
$0.07
Feb 25
$0.07
10年成長
30.2%
5年成長
69.52%
3年成長
不適用
1年成長
不適用

財報

4May預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
下一步
0.83
1.03
1.24
1.44
預期EPS
0.8825998239
實際EPS
不適用

財務

9.81%利潤率
有盈利
2019
2020
2021
2022
2023
2024
2.76B營收
270.39M淨利

分析師評級

$110.71平均目標價
最高預估為 123.00。
來自過去6個月內的 8 則評分。這不是投資建議。
買入
38%
持有
63%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 PKI 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Show more...
執行長
Dr. Prahlad R. Singh Ph.D.
員工
16700
國家
US

上市

0 Comments

分享你的想法

FAQ

PERKINELMER INC 今天的股價是多少?
PKI 目前價格為 $115.24 USD,過去 24 小時下跌了 -0.91%。在圖表上更密切關注 PERKINELMER INC 股票的表現。
PERKINELMER INC 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,PERKINELMER INC 的股票以代號 PKI 進行交易。
PERKINELMER INC 去年的營收是多少?
PERKINELMER INC 去年的營收為 2.76BUSD。
PERKINELMER INC 去年的淨利是多少?
PKI 去年的淨收益為 270.39MUSD。
PERKINELMER INC 會發放股息嗎?
是的,PKI 的股息每 每季 發放一次。每股最新股息為 0.01 USD。截至今日,股息殖利率(FWD)% 為 0.24%。
PERKINELMER INC 有多少名員工?
截至 April 01, 2026,公司共有 16,700 名員工。
PERKINELMER INC 位於哪個產業?
PERKINELMER INC從事於Health Care產業。
PERKINELMER INC 何時完成拆股?
PERKINELMER INC 上次拆股發生於 June 04, 2001,比例為 2:1。
PERKINELMER INC 的總部在哪裡?
PERKINELMER INC 的總部位於 US 的 Waltham。